MDX-210 bispecific antibody: Began Phase I/II trial

Medarex Inc. (MEDX), Princeton, N.J. Product: MDX-210 bispecific antibody, targeted against the HER-2/neu receptor on many cancer cells, in combination with G-CSF Indication: Breast cancer Status: Beg...